Seno’s Imagio® breast imaging system can help providers distinguish, in real-time, between benign and malignant breast lesions.
It could soon be easier for radiologists to make an in-the-moment decision about whether a breast lesion is malignant or benign.
On Jan. 19, the U.S. Food & Drug Administration (FDA) granted pre-market approval (PMA) to the Imagio® Breast Imaging System from Seno Medical Instruments, Inc. This system uses non-invasive opto-acoustic ultrasound (OA/US) to help providers determine in real-time if an identified mass will require more invasive diagnostic evaluation.
Courtesy: Seno Medical Instruments, Inc.
Currently, breast biopsies due to false positives account for more than $2 billion in healthcare costs each year. Imagio®, which comes paired with an artificial intelligence decision support tool (SenoGram®) that helps providers transition from ultrasound to OA/US, could help this number drop, company officials said, by giving radiologists the information they need to be more confident in their assessments of lesions.
“Optimizing the diagnosis of breast masses requires a combination of very high sensitivity (more than 98 percent) while simultaneously maximizing specificity and minimizing false positives and biopsies of benign masses,” said Seno’s chief medical officer A. Thomas Starvos, M.D., FACR, FSBI. “Other modalities have reported improvements in specificity, but these have often come at the expense of the desired high more than 98 percent sensitivity.”
Results from the PMA study, he said, reveal that OA/US does reach improved specificity at fixed 98-percent sensitivity -- the area of the ROC curve where radiologists decide whether to biopsy.
To attain this level of performance, OA/US brings together laser optics and grayscale ultrasound for fused functional and anatomical breast imaging. Alongside anatomical images, according to company details, the technology provides a blood map of the breast masses and the surrounding area that can reveal the presence or absence of angiogenesis and deoxygenation – two cancer hallmarks. With this data, a radiologist can better make decisions about whether to expose a patient to more diagnostic imaging.
This system is intended for use by trained radiologists to identify palpable and non-palpable breast abnormalities in adults who have been referred for diagnostic imaging breast follow-up after a screening mammogram.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
May 16th 2025Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.
BrightHeart Garners Third FDA Clearance for AI-Powered Assessments of Fetal Heart Ultrasound
May 14th 2025The latest FDA 510(k) clearance is for B-Right Views, an AI-enabled device, which provides automated detection of required views necessary for second- and third-trimester fetal heart ultrasound exams.